REFERENCES
- Panchagnula R, Agrawal S, Ashokraj Y, Varma MVS, Sateesh K, Bhardwaj V, Bedi S, Gulati I, Parmar J, Kaul CL, Blomberg B, Fourie B, Roscignio G, Wire R, Laing R, Evans P, Moore T. Fixed dose combination for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol 2004; 26: 703–721
- Moulding T, Dutt AK, Reichman LB. Fixed dose combinations of antituberculosis medications to prevent drug resistance. Ann. Int. Med. 1995; 122: 951–954
- Onyebujoh P, Zumla A, Ribeiro I, Rustomjee R, Mwaba P, Gomes S, Grange JM. Treatment of tuberculosis: present status and future prospects. Bull. WHO. 2005; 83: 857–865
- Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutics drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995; 12: 413–420
- Dressman JB. Dissolution testing of immediate release products and its application to forecasting in vivo performance. JB Dressman, H Lennernas. Marcel Dekker, Inc, New York 2000; 155–181, Oral Drug Absorption (Prediction and Assessment).
- Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998; 15: 698–705
- Panchagnula R, Rungta S, Sancheti P, Agrawal S, Kaul CL. In vitro evaluation of food effect on the bioavailability of rifampicin from antituberculosis fixed dose combination formulations. IL Farmaco 2003; 58: 1099–1103
- Agrawal S, Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int. J. Pharm 2004; 287: 97–112
- Agrawal S, Panchagnula R. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharmaceut Drug Disposit 2005; 26: 321–334